🇺🇸 FDA
Patent

US 6482417

Stable pharmaceutical formulation comprising torsemide modification II

expired A61KA61K31/44A61K9/20

Quick answer

US patent 6482417 (Stable pharmaceutical formulation comprising torsemide modification II) held by TEVA PHARMACEUTICAL INDUSTRIES, LTD. expires Mon Nov 14 2022 00:00:00 GMT+0000 (Coordinated Universal Time). Status: expired.

Key facts

Applicant
TEVA PHARMACEUTICAL INDUSTRIES, LTD.
Grant date
Tue Nov 19 2002 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Nov 14 2022 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
19
CPC classes
A61K, A61K31/44, A61K9/20, A61P, A61P7/10